2',2'-difluoro-2'-deoxyuridine: structure given in first source; metabolic deamination product of gemcitabine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
2',2'-difluoro-2'-deoxyuridine : A pyrimidine 2'-deoxyribonucleoside that is uridine in which the hydroxy group at position 2' has been replaced by two fluoro substituents. It is a metabolite of the drug gemcitabine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 13922189 |
| SCHEMBL ID | 12170413 |
| MeSH ID | M0224630 |
| Synonym |
|---|
| FT-0666818 |
| FT-0667885 |
| SCHEMBL12170413 |
| 2',2'-difluoro-2'-deoxyuridine |
| mfcd00871912 |
| 1-[(4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione |
| FIRDBEQIJQERSE-UHFFFAOYSA-N , |
| AKOS032947869 |
| 1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione |
| SY070231 |
| 1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-2-tetrahydrofuryl]pyrimidine-2,4(1h,3h)-dione |
| PD130776 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "To improve bioavailability and provide resistance to deamination, an array of gemcitabine (dFdC) prodrugs carrying the acyl modifications has been successful in the optimization of pharmacokinetic properties of dFdC, but the reports about 4-N-carbobenzoxy-dFdC (Cbz-dFdC), a dFdC prodrug bearing alkyloxycarbonyl modification, are relatively rare." | ( Simultaneous determination of gemcitabine prodrug, gemcitabine and its major metabolite 2', 2'-difluorodeoxyuridine in rat plasma by UFLC-MS/MS. Aa, L; Fei, F; Hao, K; Jiang, W; Liu, J; Lu, L; Pei, X; Peng, Y; Sun, Y; Wang, G; Wang, J; Zhen, L, 2018) | 0.48 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " These data can be used to rationally design gemcitabine dosage regimes for canine oncology patients and as a basis for future investigations on the in vivo intracellular accumulation of gemcitabine triphosphate in dogs." | ( Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics. Freise, KJ; Martín-Jiménez, T, 2006) | 0.33 |
| "Pancreatic ductal adenocarcinoma tumour tissue from genetically engineered mouse models of pancreatic cancer (KP ( FL/FL ) C and KP ( R172H/+) C) was collected after dosing the mice with gemcitabine." | ( A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy. Bapiro, TE; Cook, N; Frese, KK; Goldgraben, MA; Griffiths, JR; Jacobetz, MA; Jodrell, DI; Madhu, B; Olive, KP; Richards, FM; Smith, DM; Tuveson, DA, 2011) | 0.37 |
| "To develop and internally validate a population pharmacokinetic model for gemcitabine and its metabolite 2',2'-difluorodeoxyuridine (dFdU); and to evaluate its predictive perfomance for personalizing the dosage used in cancer patients." | ( [Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients]. Duart-Duart, MJ; Escudero-Ortiz, V; Pérez-Ruixo, JJ; Ramón-López, A; Valenzuela, B, ) | 0.13 |
| "The population pharmacokinetic model adequately characterised the gemcitabine and dFdU plasma concentrations in the study population over time, and can be used to accurately and precisely optimise gemcitabine dosing regimens in cancer patients." | ( [Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients]. Duart-Duart, MJ; Escudero-Ortiz, V; Pérez-Ruixo, JJ; Ramón-López, A; Valenzuela, B, ) | 0.13 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.27) | 18.2507 |
| 2000's | 22 (50.00) | 29.6817 |
| 2010's | 20 (45.45) | 24.3611 |
| 2020's | 1 (2.27) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 7 (15.22%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 3 (6.52%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 36 (78.26%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||